第61回日本神経学会学術大会

セッション情報

印刷

シンポジウム

[S-29] シンポジウム29
Preparing for disease-modifying therapies in PD – From biomarkers, animal models to novel therapeutic approach

2020年9月1日(火) 10:45 〜 12:15 第06会場 (岡山コンベンションセンター 2F レセプションホール)

座長：Sue Carolyn（The University of Sydney）,荒若 繁樹（大阪医科大学内科学IV脳神経内科）

[S-29-1] Updates of Liquid biomarkers in PD

○Chin-Hsien Lin, Chau-chung Wu, Ming-jang Chiu (National Taiwan University Hospital)

For the realization of disease-modifying therapies (DMT) in PD, appropriate animal models for the preclinical study and early and progression biomarkers in PD are essential. As a target of DMT much attention have been paid for mitochondria and alpha synuclein, especially. The aim of this symposium is, 1) to update recent findings in biomarkers and animal models in PD including its prodromal stage, and 2) to introduce novel therapeutic approach, focusing on mitochondria and alpha-synuclein which are the key players in idiopathic PD.

[S-29-2] パーキンソン病におけるリキッドバイオマーカー研究と抗パーキンソン病薬の疾患修飾の可能性

○荒若 繁樹 (大阪医科大学内科学IV教室脳神経内科)

For the realization of disease-modifying therapies (DMT) in PD, appropriate animal models for the preclinical study and early and progression biomarkers in PD are essential. As a target of DMT much attention have been paid for mitochondria and alpha synuclein, especially. The aim of this symposium is, 1) to update recent findings in biomarkers and animal models in PD including its prodromal stage, and 2) to introduce novel therapeutic approach, focusing on mitochondria and alpha-synuclein which are the key players in idiopathic PD.

[S-29-3] 疾患修飾療法をめざしたパーキンソン病動物モデルの開発

○山門 穂高 (京都大学医学部附属病院 脳神経内科)

For the realization of disease-modifying therapies (DMT) in PD, appropriate animal models for the preclinical study and early and progression biomarkers in PD are essential. As a target of DMT much attention have been paid for mitochondria and alpha synuclein, especially. The aim of this symposium is, 1) to update recent findings in biomarkers and animal models in PD including its prodromal stage, and 2) to introduce novel therapeutic approach, focusing on mitochondria and alpha-synuclein which are the key players in idiopathic PD.

[S-29-4] Novel therapeutic strategies targeting mitochondria

○Carolyn M. Sue1,2 (1.Kolling Institute of Medical Research, 2.University of Sydney)

For the realization of disease-modifying therapies (DMT) in PD, appropriate animal models for the preclinical study and early and progression biomarkers in PD are essential. As a target of DMT much attention have been paid for mitochondria and alpha synuclein, especially. The aim of this symposium is, 1) to update recent findings in biomarkers and animal models in PD including its prodromal stage, and 2) to introduce novel therapeutic approach, focusing on mitochondria and alpha-synuclein which are the key players in idiopathic PD.

[S-29-5] シヌクレイノパチーに対する疾患修飾治療

○中森 雅之 (大阪大学 医学系研究科 神経内科学)

For the realization of disease-modifying therapies (DMT) in PD, appropriate animal models for the preclinical study and early and progression biomarkers in PD are essential. As a target of DMT much attention have been paid for mitochondria and alpha synuclein, especially. The aim of this symposium is, 1) to update recent findings in biomarkers and animal models in PD including its prodromal stage, and 2) to introduce novel therapeutic approach, focusing on mitochondria and alpha-synuclein which are the key players in idiopathic PD.